AnaptysBio, Inc. ANAB · Stock Open AnaptysBio, Inc. in new tab
AnaptysBio, Inc. Analysis (ANAB)
Is AnaptysBio, Inc. a good investment? AnaptysBio, Inc. (ANAB) is currently trading at 48.63 USD. Market analysts have a consensus price target of 88.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: AnaptysBio, Inc. is expected to release its next earnings report on Nov. 10, 2026. The market consensus estimate for Forward EPS is 5.54.
Investor FAQ
Does AnaptysBio, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is AnaptysBio, Inc.?
AnaptysBio, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -1.02.
Company Profile
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Split Date | Split Ratio to 1 |
|---|---|
| April 20, 2026 | 1.5 |
Community Discussion